Journal
CURRENT HEMATOLOGIC MALIGNANCY REPORTS
Volume 13, Issue 6, Pages 534-542Publisher
CURRENT MEDICINE GROUP
DOI: 10.1007/s11899-018-0482-6
Keywords
CAR-T; DLBCL; Axi-cel; CTL019; Liso-cel; Chimeric antigen receptor
Categories
Ask authors/readers for more resources
Purpose of ReviewThis article will review the use of anti-CD19 CAR-T therapy used in relapsed/refractory diffuse large B cell lymphoma.Recent FindingsThe clinical outcomes, safety analysis, and other relevant considerations will be discussed with an emphasis on the most recently published data regarding the ZUMA-1, JULIET, and TRANSCEND NHL-001 trials.SummaryAnti-CD19 CAR-T therapy is an exciting new therapy now approved and available to patients with relapsed/refractory diffuse large B cell lymphoma. Secondary to the increasing success and availability of these products, caregivers should expect to become familiar with the indications, toxicity, and limitations of these treatment options and when patients should be considered for referral.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available